Clinical Trials
19 trialsNCT07155226 2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2 Recruiting
NCT04771130 2026-04-23
A Study of BGB-11417 in Participants With Myeloid Malignancies
BeOne Medicines
Phase 1/2 Recruiting
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06541067 2026-01-26
POSALLO
Nantes University Hospital
Phase 2 Recruiting
NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04825275 2026-01-23
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT03828773 2025-12-09
PTX3AML
Centre Hospitalier Universitaire Vaudois
Phase NA Recruiting
NCT03763396 2024-03-08
Azoles Targeting Recurrent High Grade Gliomas
University Health Network, Toronto
Phase EARLY_PHASE1 Not yet recruiting
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT03796533 2022-02-24
Posa-Pk
Hospices Civils de Lyon
Phase NA Unknown
NCT02358499 2020-12-22
Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children
Children's Mercy Hospital Kansas City
Phase 1 Completed
NCT02875743 2020-04-02
King's Invasive Aspergillosis Study II
King's College Hospital NHS Trust
Phase 4 Completed
NCT03760445 2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2 Withdrawn
NCT00936117 2019-02-27
Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01200355 2018-05-07
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Phase 4 Completed
NCT03036046 2018-02-15
SAFEGUARDFP
F2G Biotech GmbH
Phase 1/2 Withdrawn
NCT00686543 2017-04-07
Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00750737 2016-09-29
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01901172 2015-08-18
A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed